Patent Application
20230348882
The disclosure relates to the technical field of production by a biological enzyme method, in particular to a fructosamine deglycase vector, a transgenic cell line and a genetic engineering bacteria expressing fructosamine deglycase, and use of fructosamine deglycase.
Glucosamine (GlcN), i.e. 2-amino-2-deoxy-D-glucose, has important physiological functions for human body, and is widely used in food, health care products, medicines and other fields. In medical clinic, it can be used for treating bone and joint diseases, as a drug for treating rheumatoid arthritis, or as an additive in food for infants and young children. With the further improvement of the quality of life and the aggravation of population aging, the global demand for glucosamine medicines and food nutrition and health products will continue to increase.
There are two traditional methods for preparing glucosamine. One is to hydrolyze chitin. However, this process is restricted by seasonal influence of raw materials, complexity of hydrolysis process, large amount of acid and alkali, and environmental pollution. The other is to produce N-acetylglucosamine by microbial fermentation, and then glucosamine can be prepared by hydrolysis. Microbial fermentation has been widely used. In recent years, Escherichia coli, Bacillus subtilis and fungi modified by metabolic engineering have been developed to produce glucosamine, but it has defects of low yield, high cost and complex refining process.
The objective of the disclosure is to provide a fructosamine deglycase vector, a transgenic cell line and a genetic engineering bacteria expressing fructosamine deglycase, and use of fructosamine deglycase. The method provided by the disclosure has sufficient substrate sources, which is not limited by raw materials, has mild preparing conditions, little environmental pollution, high reaction specificity, less impurities, which is easy for downstream separation and purification, and has low production cost and high glucosamine yield.
The present disclosure provides a method for catalyzing a transfer of amino from an amino donor compound to an amino receptor compound, comprising: catalyzing the transfer of amino from an amino donor compound to an amino receptor compound by using an enzyme, or an expression vector or cloning vector expressing the enzyme, or a transgenic cell line and a genetic engineering bacteria expressing the enzyme; where the enzyme comprises:
In some embodiments, the amino donor compound comprises amino acids.
In some embodiments, the amino receptor compound comprises saccharide.
The present disclosure further provides use of fructosamine deglycase in the production of glucosamine and/or ketocarboxylic acid, where an amino acid sequence of fructosamine deglycase is set forth in SEQ ID NO:1.
The present disclosure further provides a method for producing glucosamine and/or ketocarboxylic acid, comprising: performing an amino conversion by using an enzyme of fructosamine deglycase, or an expression vector or cloning vector expressing the fructosamine deglycase, or a transgenic cell line and a genetic engineering bacteria expressing the fructosamine deglycase, and using amino acids and saccharides as substrates to obtain glucosamine and/or ketocarboxylic acid; an amino acid sequence of the fructosamine deglycase is set forth in SEQ ID NO:1.
In some embodiments, the saccharide comprises one or more of starch, glucose, fructose and fructose-6-phosphate.
In some embodiments, the amino acid comprises alanine, glutamic acid, aspartic acid or glutamine.
In some embodiments, the conditions of the amino conversion comprise: a pH value of 6-8 and a temperature of 30-50° C.
In some embodiments, the enzyme in the method further comprises fructokinase, and an amino acid sequence of the fructokinase is set forth in SEQ ID NO:3.
The present disclosure further provides a vector of fructosamine deglycase, where the vector comprises a skeleton vector and a gene encoding the fructosamine deglycase; and a nucleotide sequence of the gene encoding the fructosamine desugarase is set forth in SEQ ID NO:2.
The present disclosure further provides a transgenic cell line expressing fructosamine deglycase, where a nucleotide sequence of a gene encoding fructosamine deglycase is set forth in SEQ ID NO:2.
The present disclosure further provides a genetic engineering bacteria expressing fructosamine deglycase, where a nucleotide sequence of a gene encoding fructosamine deglycase is set forth in SEQ ID NO:2.
The present disclosure further provides a method for producing fructosamine deglycase expressed by the genetic engineering bacteria above, comprising: performing liquid culture and induction to the genetic engineering bacteria to obtain fructosamine deglycase.
The present disclosure further provides a compound enzyme for co-producing glucosamine and ketocarboxylic acid, where the compound enzyme comprises fructosamine deglycase and fructokinase; an amino acid sequence of the fructosamine desugarase is set forth in SEQ ID NO:1; an amino acid sequence of the fructokinase is set forth in SEQ ID NO: 3.
The present disclosure further provides a method for co-producing glucosamine and ketocarboxylic acid by using the compound enzyme above, comprising: mixing fructose and fructokinase for phosphorylation to obtain a fructose-6-phosphate; mixing the fructose-6-phosphate, amino acid and fructosamine deglycase for amino transfer to obtain glucosamine and ketocarboxylic acid.
The present disclosure provides a method for catalyzing a transfer of amino from an amino donor compound to an amino receptor compound. The method provided by the disclosure has sufficient substrate sources, which is not limited by raw materials, has mild preparing conditions, little environmental pollution, high reaction specificity, less impurities, which is easy for downstream separation and purification, and has low production cost and high glucosamine yield. In a specific embodiment of the disclosure, gene sequence synthesis is conducted to the fructokinase (GenBank: ESD97983.1) derived from Escherichia coli 908658 and fructosamine deglycase (GenBank: AOR99552.1) derived from Bacillus subtilis by a gene synthesis method, and the resulting sequence is constructed in plasmid pCold II and stored in Escherichia coli JM109. According to the disclosure, the fructokinase protein and fructosamine deglycase protein are respectively obtained by successfully expressing Escherichia coli BL21 with high solubility, and the expressed biological enzyme protein is purified. According to the disclosure, the biological activity of the obtained recombinant fructokinase and recombinant fructosamine deglycase is verified, and it is found that starch, glucose, fructose and fructose-6-phosphate can be synthesized into glucosamine by performing phosphorylation and transamination for the fructokinase and fructosamine deglycase in turn, and α-ketoglutarate can be generated by using glutamic acid at the same time, or pyruvic acid can be generated by transamination of alanine at the same time. Data show that fructokinase and fructosamine deglycase of the disclosure have good function of synthesizing glucosamine and pyruvic acid or α-ketoglutarate, and have great application potential. The method of the disclosure can greatly reduce the production cost of glucosamine and/or ketocarboxylic acid, amino acid and/or saccharide, be used as raw materials in pharmaceutical industry and food production industry, and has important significance.
The present disclosure provides a method for catalyzing a transfer of amino from an amino donor compound to an amino receptor compound, comprising: catalyzing the transfer of amino from an amino donor compound to an amino receptor compound by using an enzyme, or an expression vector or cloning vector expressing the enzyme, or a transgenic cell line and a genetic engineering bacteria expressing the enzyme; where the enzyme comprises:
In some embodiments, the enzyme is fructosamine deglycase (FrIB), a nucleotide sequence of the gene encoding the enzyme is set forth in SEQ ID NO:2:
The fructosamine deglycase has the function of catalyzing the transfer of amino from an amino donor compound to an amino receptor compound. Transamination is conducted by the fructosamine deglycase of the present disclosure.
In some embodiments, the amino donor compound preferably includes amino acids. In some embodiments, the amino receptor compound preferably includes saccharide. In some embodiments, the saccharide preferably includes one or more of starch, glucose, fructose and fructose-6-phosphate.
The method of the disclosure has the advantages of cheap raw materials, abundant sources, low production cost, environmental friendliness, safety to human bodies and the like.
The disclosure further provides use of fructosamine deglycase in the production of glucosamine and/or ketocarboxylic acid, and an amino acid sequence of the fructosamine deglycase is set forth in SEQ ID NO:1.
The disclosure further provides a method for producing glucosamine and/or ketocarboxylic acid, comprising: performing an amino conversion by using an enzyme of fructosamine deglycase, or an expression vector or cloning vector expressing the fructosamine deglycase, or a transgenic cell line and a genetic engineering bacteria expressing the fructosamine deglycase, and using amino acids and saccharides as substrates to obtain glucosamine and/or ketocarboxylic acid; an amino acid sequence of the fructosamine deglycase is set forth in SEQ ID NO:1.
In some embodiments, the saccharide preferably includes one or more of starch, glucose, fructose and fructose-6-phosphate. In the production process of the present disclosure, transamination is preferably conducted by using fructose-6-phosphate and amino acids as substrates. The amino group of the amino acid is transferred to fructose-6 phosphate to obtain glucosamine, and the amino group is removed from the amino acid to obtain the ketocarboxylic acid. The starch, glucose and fructose of the present disclosure are preferably converted into fructose-6-phosphate before the above reaction is conducted.
In some embodiments, the amino acids preferably include alanine, glutamic acid, aspartic acid or glutamine. After amino group transformation, each amino acid will generate corresponding ketocarboxylic acid. In some embodiments, the conditions for the amino conversion preferably include: pH 6-8, temperature 30-50° C.; more preferably pH 6.7-7.5, temperature 40-50° C. In some embodiments, the enzyme used in the method preferably further comprises fructokinase, an amino acid sequence of the fructokinase is set forth in SEQ ID NO:3:
a nucleotide sequence of the fructokinase is set forth in SEQ ID NO:4:
In some embodiments, when the saccharide is fructose, the catalytic system of the present disclosure preferably contains fructosamine deglycase and fructokinase, and the use of fructokinase can convert fructose into fructose-6-phosphate, and then carry out subsequent reaction above-mentioned.
The disclosure further provides a vector of fructosamine deglycase, comprising a skeleton vector and a gene encoding fructosamine deglycase; and a nucleotide sequence of the gene encoding fructosamine deglycase is set forth in SEQ ID NO:2. In some embodiments, the vector preferably includes an expression vector or a cloning vector, and when the vector is an expression vector, the skeleton vector preferably includes pCold II, pcold I or pUC19, and more preferably pCold II.
The present disclosure further provides a transgenic cell line for expressing fructosamine deglycase, and a nucleotide sequence of the gene encoding fructosamine deglycase is set forth in SEQ ID NO:2. In some embodiments, there is no special limitation on the type and source of the cell line, and conventional commercial cell lines well known to those skilled in the art will do.
The present disclosure further provides a genetic engineering bacteria for expressing fructosamine deglycase, and a nucleotide sequence of the gene encoding fructosamine deglycase is set forth in SEQ ID NO:2. In some embodiments, the host bacteria include Escherichia coli, preferably include Escherichia coli BL21, Escherichia coli DH5u or Escherichia coli Top10, and more preferably Escherichia coli BL21.
In a specific embodiment of the disclosure, a specific recombinant Escherichia coli genetic engineering bacteria is constructed, and the constructing method preferably comprises:
The genes of fructokinase and fructosamine deglycase are searched through NCBI (National Center for Biotechnology Information) database. After finding the gene of the biological enzyme corresponding to the substrate, it is handed over to the biological company for gene synthesis, thus obtaining the above enzyme gene; the fructokinase gene is named FRK1, and the fructosamine deglycase gene is named FrIB.
Selecting pCold II as E. coli expression vector, recombinant expression vectors pCold II-FRK1 and pCold II-FrIB are constructed, and the recombinant expression plasmids pCold II-FRK1 and pCold II-FrIB are transformed into E. coli JM109, respectively, for preserving the recombinant expression vectors.
The disclosure further provides a method for producing fructosamine deglycase expressed by the genetic engineering bacteria, comprising: performing liquid culture and induction to the genetic engineering bacteria to obtain fructosamine deglycase.
In a specific embodiment of the present disclosure, after obtaining the recombinant expression vector, the method for producing fructosamine deglycase preferably comprises: positive recombinant Escherichia coli BL21/pCold II-FrIB of the electrotransformation linearized recombinant expression plasmid pCold II-FRK1 or pCold II-FrIB is cultured at 37° C. at 200 rpm until OD600=0.4-0.6; then the Escherichia coli BL21/pCold II-FrIB is transferred to 15° C. for culture, added with isopropyl β-d-1-thiogalactopyranoside (IPTG) with a final concentration of 0.4 mM, and induced the expression for 24 h with a rotation speed of 200 rpm.
The disclosure further provides a compound enzyme for co-producing glucosamine and ketocarboxylic acid, where the compound enzyme comprises fructosamine deglycase and fructokinase; an amino acid sequence of the fructosamine desugarase is set forth in SEQ ID NO:1; an amino acid sequence of the fructokinase is set forth in SEQ ID NO:3.
The disclosure further provides a method for co-producing glucosamine and ketocarboxylic acid by using the compound enzyme above, comprising: mixing fructose and fructokinase for phosphorylation to obtain a fructose-6-phosphate; mixing the fructose-6-phosphate, amino acid and fructosamine deglycase for amino transfer to obtain glucosamine and ketocarboxylic acid. In some embodiments, the amino acids preferably include alanine or glutamic acid. In some embodiments, when the amino acid is alanine, the ketocarboxylic acid is pyruvic acid; when the amino acid is glutamic acid, the ketocarboxylic acid is α-ketoglutaric acid. According to the method for co-producing glucosamine and ketocarboxylic acid, different types of ketocarboxylic acids can be prepared by changing the types of amino acids.
Specifically, the disclosure provides a method for co-producing glucosamine and pyruvic acid based on the compound enzyme described in the technical solution above, comprising: mixing fructose and fructokinase for phosphorylation to obtain a fructose-6-phosphate; mixing the fructose-6-phosphate, alanine and fructosamine deglycase and performing transamination to obtain glucosamine and pyruvic acid. The preparation method for co-producing glucosamine and pyruvic acid by enzymatic method not only meets the demand of low-cost glucosamine, but also meets the demand of quantity and price of pyruvic acid as raw material of health food. According to the disclosure, a biotransformation method, also known as a biocatalysis method, is utilized, and an extracted pure enzyme is used as a catalyst to complete transamination. At the same time, alanine is added as amino donor, which not only solves the need of amino catalyzed by enzyme, but also generates pyruvic acid as raw material of health food due to the transfer of amino in the preparation process of alanine. According to the disclosure, glucosamine and pyruvic acid are produced with high yield and low cost through a biotransformation method. According to the method, the production efficiency is improved by controlling the addition amount of enzymes, and the generation of byproducts is reduced; two products of glucosamine and pyruvic acid are obtained through simple separation, thus greatly reducing the prices of the two products.
The disclosure provides a method for co-producing amino acid and α-ketoglutarate based on the compound enzyme in the technical solution above, comprising: mixing fructose and fructokinase for phosphorylation to obtain a fructose-6-phosphate; mixing the fructose-6-phosphate, glutamic acid and fructosamine deglycase and performing transamination to obtain glucosamine and α-ketoglutarate. According to the disclosure, glutamic acid is added, and the amino group for producing glucosamine is provided by glutamic acid; in the process of enzymatic preparation, not only is glucosamine with high concentration and high purity prepared, but also glutamic acid is transformed into α-ketoglutaric acid with high added value. Therefore, glucosamine and α-ketoglutarate are prepared by enzymatic co-production. The method of the present disclosure has the advantages of low production cost, high product purity, simple preparation steps and the like.
The fructosamine deglycase vector, transgenic cell line and a genetic engineering bacteria expressing fructosamine deglycase, and use of fructosamine deglycase according to the present disclosure will be further explained in detail with specific examples below. The technical solution of the present disclosure includes but is not limited to the following examples.
Terms used in the present disclosure, unless otherwise specified, generally have meanings commonly understood by those of ordinary skills in the art.
In the following examples, various processes and methods not described in detail are conventional methods known in the art.
Acquisition of Fructokinase and Fructosamine Deglycase Genes
At first, the genes of fructokinase and fructosamine deglycase were searched through NCBI (National Center for Biotechnology Information) database. The fructokinase from Escherichia coli 908658 (GenBank: ESD97983.1) and fructosamine deglycase from Bacillus subtilis (GenBank: AOR99552.1) were obtained by gene mining, and then they were handed over to biological company for gene synthesis. In which the SnaBI and NotI restriction sites (without signal peptide) were introduced into the synthesized gene sequence, the restriction sites were protective bases, and the effective sequence was the sequence after the restriction site. And the synthesized gene sequence was stored in the plasmid pMD-19T to form a recombinant plasmid pMD-19T-FRK1 or pMD-19T-FrIB.
Transformation was conducted to the synthesized gene sequence, that is, 10 μl of ligation product was taken and added into competent cells JM109, then put on ice for 30 min, immediately put on ice after being heated at 42° C. for 90 s, then put on ice for 2 min, 1 ml LB culture medium without antibiotics was added, and it was cultured on a shaking table at 37° C. for 1h, then the transformed bacterial solution was coated on LB(Amp) blue whiteboard and cultured overnight at 37° C. Several colonies were selected from the plate for PCR identification.
At the same time, plasmid extraction was used, and clone plasmid identified as positive by PCR was extracted by plasmid extraction kit of OMEGA Company.
Construction of prokaryotic expression vectors, recombinant expression and protein expression of fructokinase and fructosamine deglycase genes
1. Construction of Prokaryotic Expression Vector
Primers of Fructosamine Deglycase:
The underlined part was the restriction site, the enzymes used were SnaB I and Not I.
Fructokinase Primer:
The underlined part was the restriction site, the enzymes used were SnaB I and Not I.
The system was digested at 37° C. for 2 hours.
The clone extraction plasmid was sequenced at both ends of AOX3 and AOX5, which further verified the correctness of the inserted target gene.
2. Expression of Recombinant Plasmid in Escherichia coli BL21
According to the operation manual of E. coli expression system, 10 μl of ligation product was taken and added into competent cells DE3, then put on ice for 30 min, immediately put on ice after being heated at 42° C. for 90 s, then put on ice for 2 min, 1 ml LB culture medium without antibiotics was added, and then it was cultured in on shaking table at 37° C. for 1h, then the transformed bacterial solution was coated on LB(Amp) blue whiteboard and cultured overnight at 37° C. Several colonies were selected from the plate for PCR identification. Compared with the bacteria transformed by empty vector, it was further verified that the target gene had been transferred into E. coli BL21.
The recombinant Escherichia coli was cultured in 25-50 mL LB medium (250 mL triangular flask) until the OD value reached 0.4-0.6, and then transferred to 15° C. for culture, and added with Isopropyl β-d-1-thiogalactopyranoside (IPTG) with a final concentration of 0.4 mM, and an induced expression was conducted for 24 h at a rotation speed of 200 rpm. Then, the bacteria were broken by ultrasonic wave and the recombinant enzyme was extracted. Meanwhile, SDS-PAGE and enzyme activity of the culture solution were determined.
Purification of Fructokinase and Fructosamine Deglycase Protein
Purification of recombinant enzyme and SDS-PAGE gel electrophoresis analysis thereof.
Protein was purified according to GE Healthcare guidelines, and SDS-PAGE analysis was carried out according to Molecular Cloning Experimental Guidelines (Third Edition). The gel concentration used was 12.5%, and the sample loading was 5-25p1.
Protein was stained with Coomassie Brilliant Blue R-250.
The experimental steps of native-SDS-PAGE include:
Activity Detection of Purified Fructokinase and Fructosamine Deglycase
1. Detection of Fructokinase Activity
Enzyme activity was determined by enzyme-linked assay. The 400 μL reaction solution included 30 mmol/L Hepes-NaOH(pH 7.5), 1 mmol/L MgCl2, 0.6 mmol/L Na2EDTA, 9 mmol/L KCl, 1 mmol/L NAD, 1 mmol/L ATP, 2 mmol/L fructose. 1 U Glc-6-P DH (from Leuconost ° C. mesotriodes), 1 U phosphoglucoisozyme (PGI, Sigma), after adding 80 μL enzyme extract at 25° C., the reaction started, and the absorption value at 340 nm was measured. The activity of fructokinase was measured as (NAD+ yield)/min, that was, the change value of NAD+ absorbance.
2. Detection of Fructosamine Deglycase Activity
Reaction System:
1 mL reaction system contained 15 mM glutamic acid, 20 mM fructose-6-pHosphate, 0.2 mL fructosamine deglycase, 2.5 mM EDTA and 100 mM buffers with different pH values (Na2HPO4—NaH2PO4, pH2.0-10.0). The above reaction systems was put into a 1.5 mL centrifuge tube, mixed evenly, and then put into PCR to react at 37° C. for 20 min, then the reaction was terminated by heating at 95° C. for 5 min. After centrifugation, the supernatant was taken to detect the production of α-ketoglutarate by high performance liquid chromatography (HPLC) to calculate the fructosamine desaccharase activity, so as to calculate the activity of fructosamine deglycase.
Testing Conditions:
The α-ketoglutarate was quantitatively analyzed by high performance liquid chromatography (HPLC). A Hypersil BDS column was used, the mobile phase was 0.1 mol·L−1 (NH4)H2PO4, with a pH of 2.65, the flow rate was 1.0 mL/min, the column temperature was 40° C., and the detection wavelength was 215 nm. The content of α-ketoglutaric acid in the reaction solution was calculated by peak area according to the external standard method.
Enzyme Activity Definition:
Under the optimum reaction temperature of 37° C., the amount of enzyme needed to catalyze the conversion of 1 μmol glutamic acid to α-ketoglutarate per minute was defined as one enzyme activity unit, namely 1U.
The enzyme activity of fructokinase was determined to be 1.6221U; the activity of fructosamine deglycase was 2.7859U.
Reaction System:
1 mM fructose; 100 mM HEPES buffer (pH 7.0); 10 mM MgCl; 15 mM glutamic acid; 2.5 mM EDTA; 10U fructosamine deglycase; 10U fructokinase. This reaction system was reacted for 1 hour and then used for detection. Through quantitative analysis of glucosamine, the reaction process was controlled. While the reaction produced glucosamine, glutamic acid was converted into α-ketoglutarate due to transamination.
Testing Conditions:
Glucosamine was quantitatively analyzed by high performance liquid chromatography (HPLC). The chromatographic column was amino column, the mobile phase was 80% acetonitrile aqueous solution, the flow rate was 0.6 mL/min, the column temperature was 40° C., and the detector was differential refraction detector. The retention time of glucosamine was about 12.7 minutes. The concentration of glucosamine was proportional to the response intensity of HPLC characteristic peak of glucosamine.
After the above experimental process, it was detected that the glucosamine produced after the reaction for 1 hour was 0.65 mM.
Reaction System:
1 mM fructose; 100 mM HEPES buffer (pH 7.0); 10 mM MgCl; 15 mM alanine; 2.5 mM EDTA; 10U fructosamine deglycase; 10U fructokinase. This reaction system was reacted for 1 hour and then used for detection. Through quantitative analysis of glucosamine, the end point of the synthetic reaction was determined. Finally, glucosamine was prepared by separation, and pyruvic acid, a health food raw material with natural characteristics, was also prepared.
Testing Conditions:
Glucosamine was quantitatively analyzed by high performance liquid chromatography (HPLC). The chromatographic column was amino column, the mobile phase was 80% acetonitrile aqueous solution, the flow rate was 0.6 mL/min, the column temperature was 40° C., and the detector was differential refraction detector. The retention time of glucosamine was about 12.7 minutes. The concentration of glucosamine was proportional to the response intensity of HPLC characteristic peak of glucosamine.
After the above experimental process, it was detected that the glucosamine produced after the reaction for 1 hour was 0.78 mM.
The above is only the preferred embodiment of the present disclosure, and it should be pointed out that for ordinary technicians in the technical field, without departing from the principle of the present disclosure, several improvements and embellishments can be made, and these improvements and embellishments should also be regarded as the protection scope of the present disclosure.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2021/109679 | 7/30/2021 | WO |
